These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 10179745)

  • 1. Knowledge generating in expert systems as support of immunological investigations.
    Biljana M; Jelena M; Milorad R; Branislav J; Nebojsa A
    Stud Health Technol Inform; 1997; 43 Pt B():642-6. PubMed ID: 10179745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms.
    Ruffini E; Asioli S; Filosso PL; Lyberis P; Bruna MC; Macrì L; Daniele L; Oliaro A
    Ann Thorac Surg; 2009 Feb; 87(2):365-71; discussion 371-2. PubMed ID: 19161739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies on the prognostic significance of tumor infiltrating leukocytes in solid human tumors.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(3A):1759-68. PubMed ID: 10928105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Subpopulations of TIL in renal cell carcinoma and their clinical significance].
    Li Y; Hou S; Zhang X; Zhang G; Zhu J; Wang X
    Zhonghua Wai Ke Za Zhi; 1998 May; 36(5):314-6. PubMed ID: 11825399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
    Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
    Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
    Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
    Stopeck AT; Gessner A; Miller TP; Hersh EM; Johnson CS; Cui H; Frutiger Y; Grogan TM
    Clin Cancer Res; 2000 Oct; 6(10):3904-9. PubMed ID: 11051236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
    Tomsová M; Melichar B; Sedláková I; Steiner I
    Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A development protocol for a diagnostic DSS.
    O YL; ter Burg WJ; ter Braak EW; Neijt JP; Wiegerinck WA; Nijman MJ; Kappen HJ
    Stud Health Technol Inform; 1999; 68():755-8. PubMed ID: 10724995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method.
    Loughlin PM; Cooke TG; George WD; Gray AJ; Stott DI; Going JJ
    J Immunol Methods; 2007 Apr; 321(1-2):32-40. PubMed ID: 17324439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P; Caliliw R; Belldegrun A; Bonavida B
    Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parameter evaluation of the differential diagnosis of female urinary incontinence for the construction of an expert system.
    Laurikkala J; Juhola M; Penttinen J; Aukee P
    Stud Health Technol Inform; 1997; 43 Pt B():671-5. PubMed ID: 10179751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma.
    Lockhart DC; Chan AK; Mak S; Joo HG; Daust HA; Carritte A; Douville CC; Goedegebuure PS; Eberlein TJ
    Surgery; 2001 Jun; 129(6):749-56. PubMed ID: 11391375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
    Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
    Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
    Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of tumor-infiltrating lymphocyte from oral squamous cell carcinoma with FN enhances its adhesion and cytotoxicity.
    Yang H; Li J; Zhao Y; Li Z
    Chin J Dent Res; 1999 Dec; 2(3-4):49-53. PubMed ID: 10863417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualizing generic decision models using assessments as evidence.
    Scott GC; Shachter RD
    J Biomed Inform; 2005 Aug; 38(4):281-97. PubMed ID: 16084471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal dynamics of tumor-infiltrating lymphocytes.
    Yu R; Fujio K; Tahara H; Araki Y; Yamamoto K
    Eur J Immunol; 2005 Jun; 35(6):1754-63. PubMed ID: 15902685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.